CLSA Hosts Congressional Briefing on America’s Biodefense and Emergency Preparedness
May 17, 2018
By Adam Lotspike
On May 14, CLSA hosted a congressional briefing on America’s biodefense and emergency preparedness, with a focus on why reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) is critical for ensuring our nation’s biodefense and pandemic preparedness.
The event was convened in collaboration with Reps. Susan Brooks (R-Ind.) and Anna G. Eshoo (D-Silicon Valley) as co-chairs of the Congressional Biodefense Caucus. CLSA cohosted the event along with a dozen other state and regional life sciences associations, including San Diego-based Biocom, Healthcare Institute of New Jersey (HINJ), Life Sciences Pennsylvania, and Michigan Bio, as well as BioNJ, Bio Utah, Bio West Virginia, Colorado Bioscience Association, Delaware Bio, Indiana Medical Device Manufacturers Council (IMDMC), Massachusetts Bio, MassMEDIC, Medical Alley (MN), MedTech of New York and North Carolina Bio.
CLSA’s Jennifer Nieto Carey, Vice President of Federal Government Relations and Alliance Development, moderated the briefing, which featured perspectives of expert panelist discussants including Dr. Rick Bright, Deputy Assistant Secretary for Preparedness and Response (ASPR), and Director of the Biomedical Advanced Research and Development Authority (BARDA), at the US Department of Health and Human Services (HHS); Kelly Childress Lange, Partner at East End Group, and former Healthcare Policy Advisor to retired Rep. Mike Rogers (R-Mich.); Dr. Rajeev Venkayya, President of the Global Vaccine Business Unit at Takeda Pharmaceuticals; Dr. Clem Lewin, Associate Vice President of Research & Development Strategy at Sanofi; and, Chris French, Senior Vice President of Government Affairs at Emergent BioSolutions and Co-Chair of the Alliance for Biosecurity. The discussion was focused around educating congressional staff on our nation’s biodefense and emergency preparedness efforts and how government and industry work together to develop the vaccines, drugs, and diagnostics needed to protect public health. The event attracted a sizeable standing room-only crowd, and was well attended by congressional staff and other stakeholders.
CLSA continues to support efforts to encourage renewal of PAHPA and proper funding of biodefense and pandemic preparedness priorities. Last month (April), CLSA supported a multi-sector stakeholder letter urging reauthorization of PAHPA, and another letter recommending robust funding levels for priority programs that have been critical to the nation’s preparedness and response to pandemic and CBRN threats. A copy of the PAHPA reauthorization letter is available here, and the letter supporting biodefense funding is available here.
Questions? Please contact Jenny Nieto Carey, CLSA’s Vice President of Federal Government Relations & Alliance Development (email@example.com).